Pamela M Holland

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. pmc Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours
    Y Pan
    Department of Molecular Sciences, Amgen Inc, 1201 Amgen Court West, Seattle, WA 98119, USA
    Br J Cancer 105:1830-8. 2011
  2. ncbi request reprint Death receptor agonist therapies for cancer, which is the right TRAIL?
    Pamela M Holland
    Therapeutic Innovation Unit, Amgen Inc, 360 Binney Street, Cambridge, MA 02142, United States Electronic address
    Cytokine Growth Factor Rev 25:185-93. 2014
  3. doi request reprint Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL
    Pamela M Holland
    Therapeutic Innovation Unit, Amgen Inc, 360 Binney Street, AMA1 7 L 12, Cambridge, MA 02142, USA
    Cancer Lett 332:156-62. 2013
  4. ncbi request reprint RIP4 is an ankyrin repeat-containing kinase essential for keratinocyte differentiation
    Pamela Holland
    Immunex Corporation, 51 University Street, Seattle, WA 98101, USA
    Curr Biol 12:1424-8. 2002
  5. ncbi request reprint Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis
    Pamela M Holland
    Department of Oncology, Amgen Inc, Seattle, WA 98119, USA
    Cancer Biol Ther 9:539-50. 2010
  6. doi request reprint RIP4 regulates epidermal differentiation and cutaneous inflammation
    Ryan B Rountree
    Department of Oncology, Amgen, Seattle, Washington, USA
    J Invest Dermatol 130:102-12. 2010
  7. ncbi request reprint Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells
    Mara S Lippa
    Department of Oncology, Amgen Inc, 1201 Amgen Ct West, Seattle, WA 98119, USA
    Apoptosis 12:1465-78. 2007
  8. ncbi request reprint Purification, cloning, and characterization of Nek8, a novel NIMA-related kinase, and its candidate substrate Bicd2
    Pamela M Holland
    Immunex Corporation, Seattle, Washington 98101, USA
    J Biol Chem 277:16229-40. 2002

Collaborators

Detail Information

Publications8

  1. pmc Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours
    Y Pan
    Department of Molecular Sciences, Amgen Inc, 1201 Amgen Court West, Seattle, WA 98119, USA
    Br J Cancer 105:1830-8. 2011
    ..A Phase1a trial evaluated the safety and tolerability of dulanermin in patients with advanced tumours. One aim was to develop and validate pharmacodynamic biomarkers to monitor dulanermin activity in patient serum...
  2. ncbi request reprint Death receptor agonist therapies for cancer, which is the right TRAIL?
    Pamela M Holland
    Therapeutic Innovation Unit, Amgen Inc, 360 Binney Street, Cambridge, MA 02142, United States Electronic address
    Cytokine Growth Factor Rev 25:185-93. 2014
    ..Results from clinical studies and insight into why current agents have failed to yield robust responses are discussed. In addition, new strategies for the development of next generation death receptor agonists are reviewed. ..
  3. doi request reprint Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL
    Pamela M Holland
    Therapeutic Innovation Unit, Amgen Inc, 360 Binney Street, AMA1 7 L 12, Cambridge, MA 02142, USA
    Cancer Lett 332:156-62. 2013
    ..In this review, current knowledge and new insights about Apo2L/TRAIL signaling is discussed with the focus on the development of Apo2L/TRAIL as a cancer therapeutic...
  4. ncbi request reprint RIP4 is an ankyrin repeat-containing kinase essential for keratinocyte differentiation
    Pamela Holland
    Immunex Corporation, 51 University Street, Seattle, WA 98101, USA
    Curr Biol 12:1424-8. 2002
    ..Instead, abnormal hair follicle development and epidermal dysplasia, indicative of progression into a more pathologic state, are observed. Thus, RIP4 is a critical component of a novel pathway that controls keratinocyte differentiation...
  5. ncbi request reprint Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis
    Pamela M Holland
    Department of Oncology, Amgen Inc, Seattle, WA 98119, USA
    Cancer Biol Ther 9:539-50. 2010
    ....
  6. doi request reprint RIP4 regulates epidermal differentiation and cutaneous inflammation
    Ryan B Rountree
    Department of Oncology, Amgen, Seattle, Washington, USA
    J Invest Dermatol 130:102-12. 2010
    ..These data suggest that RIP4 functions in the epidermis through PKC-specific signaling pathways to regulate differentiation and inflammation...
  7. ncbi request reprint Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells
    Mara S Lippa
    Department of Oncology, Amgen Inc, 1201 Amgen Ct West, Seattle, WA 98119, USA
    Apoptosis 12:1465-78. 2007
    ..Elucidation of the factors that contribute to Apo2L/TRAIL resistance in tumor cells may provide insight into combination therapies with Apo2L/TRAIL in a clinical setting...
  8. ncbi request reprint Purification, cloning, and characterization of Nek8, a novel NIMA-related kinase, and its candidate substrate Bicd2
    Pamela M Holland
    Immunex Corporation, Seattle, Washington 98101, USA
    J Biol Chem 277:16229-40. 2002
    ..Treatment of cells with nocodazole leads to dramatic reorganization of Bicd2, and correlates with Nek8 phosphorylation. This may be indicative of a role for Nek8 and Bicd2 associated with cell cycle independent microtubule dynamics...